Biocon Biologics Bengaluru facility gets 5 USFDA observations
Bengaluru: Biocon has announced that the U.S. Food and Drug Administration (FDA) has concluded a routine cGMP inspection with five observations at Biocon Biologics' Drug Substance facility at Biocon Campus in Bengaluru, India.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated, global biosimilars company. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other noncommunicable diseases.
Read also: Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.